Yükleniyor... / Loading...
This study examines how several first-line drug combinations used for uncomplicated malaria (Artemether + Lumefantrine, Dihydroartemisinin-piperaquine, Artesunate-Amodiaquine, and Pyronaridine-artesunate) are implemented and molecularly monitored within the health system in Western Kenya. People aged 5 years and older with confirmed malaria could take part. It was a study without an assigned phase and has been completed.
The summary above is a plain-language rendering of the official record. The original English title is shown for reference.
Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.
Inclusion Criteria: * Age 5 years or older * Clinical diagnosis of uncomplicated malaria * Confirmed Plasmodium falciparum infection by rapid diagnostic test (RDT) or microscopy * Presenting at participating health facility for malaria treatment * Able and willing to provide informed consent (or parental/guardian consent for minors under 18 years) * Resident of study catchment area * For molecular surveillance substudy: willingness to provide dried blood spot sample Exclusion Criteria: * Pregnant women (due to contraindications for some study medications in first trimester and lack of safety data) * Children under 5 years of age (due to lack of pediatric formulations for some study medications) * Severe or complicated malaria requiring parenteral treatment or hospitalization * Known hypersensitivity or contraindication to any of the study artemisinin-based combination therapies * Unable to take oral medications * Previous participation in current treatment episode (repeat visits) * Concurrent participation in other interventional malaria treatment studies